Loading clinical trials...

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

NCT05224492•Sunshine Specialty Health Care

View on ClinicalTrials.gov

Summary

Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more.
•BMI increase of 10% or more since initiation of HIV treatment over a year period.
•BMI equal to or greater than 30.
•18-85 years of age.

Exclusion Criteria

•Cancer
•Pregnancy or breastfeeding
•Intolerance to cruciferous vegetables
•Intolerance to sulforaphane
•Gluten Intolerance
•Creatinine \> 1.3 mg/dL
•GFR \< 60
•AST or ALT \> 1.5 times upper limit of normal.
•White cell count \< 2000 cells per ml.
•Hemoglobin \< 10.5 g/dL.
+1 more criteria

Key Dates

Start Date

February 21, 2022

Primary Completion Date

July 21, 2022

Completion Date

September 21, 2022

Last Updated

February 7, 2022

Enrollment

ESTIMATED participants

Conditions

HIV Infections

Interventions

Sulforaphane

DRUG

Placebo

OTHER

Contacts

Johannah G Katz

CONTACT

4074894750 Johannahfgiron@gmail.com

Jose A. Giron, MD

CONTACT

4078885980 Joseoidc@aol.com

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Comprehensive HIV and Harm Prevention Via Telehealth

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706